"Cardiovascular Medicine Frontiers" released the latest research results

According to the "China Cardiovascular Health and Disease Report 2021", the incidence and mortality of cardiovascular disease in my country are still at the top of the list. Two of them died of cardiovascular disease every 5 cases. severe. How to prevent and maintain cardiovascular health more effectively from the source is an important topic in the field of cardiovascular health.

2022年8月22日，心血管领域国际权威SCI杂志《心血管医学前沿》发表了一篇题为“Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1062 participants”[1]，即“ Research articles on the clinical study of Natto Kinase on 1062 cases of atherosclerosis and hyperlipidemia. This clinical study proves that the 10800 Fu Na bean kinase dose (FU [Fibrinolytic Unit) represents the active unit of nattoin kinase -soluble fibrin [artificial blood embolism], which has become a universal active label unit that measures the quality of nan bean kinase products). It is significantly effective to improve the progress of atherosclerosis and the management of hypertrophy.

In the field of Natto kinase research, this is the largest clinical study that has so far and published in the highest influence factor.

(The picture shows a screenshot of the research article)

Study retrospectively analyzed from 2016 to 2020, 1062 participants took natto kinase preparation products (dosage of 3600fu/time, 3 times/day, that is, 10800fu per day) 12 months later. Before and after using nattoinase, the participants performed blood lipid levels and B -ultrasound.

The results show that nattoin kinase can effectively control the progress of atherosclerosis and hyperlipidemia in the dose of 10800 FU /day, and significantly improve the level of blood lipids, ranging from 66.5%to 95.4%, and did not use Na Na Na Na. Obvious adverse reactions related to bean kinase.

Specifically, taking 10800fu/day dose of nattoinobacinase is 12 months. The internal middle membrane thickness of patients with atherosclerotic plaques is reduced by 21.7%, and the effective rate is 77.7%; the area of ​​the plaque area is reduced by 36.0%, the effective rate is effective 66.5%; the total cholesterol of patients with hyperlipidemia decreased by 15.9%, and the effective rate was 95.4%; the triple lipids of glycerin decreased by 15.7%, and the effective rate was 85.2%; the low -density lipoprotein cholesterol was reduced by 18.1%, the effective rate was 84.3%; the high -density lipid -protein cholesterol rose to rise. 15.8%height, an efficient rate of 89.1%.

(The picture shows the effects of comparative natto kinase on the blood lipid condition and arteriosclerosis progress of different gender participants)

People with a weight index (BMI) are more sensitive to nan bean kinase.

(The picture shows the impact of the blood lipid conditions and arteriosclerosis progress of Natto Kinase on obesity (BMI> 27.5) and non -obese participants)

The lipids of natto lipidase are even more prominent among smoking and drinking subjects.

(The picture shows the impact of comparative blood lipid status and arteriosclerosis progress of Natto kinase on smoking and non -smoking participants)

(The picture shows the impact of the blood lipid conditions and arteriosclerosis progress of natto kinase on drinking and non -drinking participants)

Regular and regular exercise can further enhance the effects of nan bean kinase controlling atherosclerosis and hyperlipidemia.

In

In the study, some participants also took vitamin K2 (MK-7) at the same time, and the dose was 180 μg per day; the other part of the participants took Aspirin at the same time, the dose was 100 mg per day. It was found that taking vitamin K2 (MK-7) and nattoinase have a synergistic effect on the blood lipids of hyperlipidemia patients; while taking aspirin at the same time will have synergistic effects on blood lipid spectrum and inhibit the progress of atherosclerosis, which means that this means The favorable changes in blood lipid spectrum and the inhibition of the progress of atherosclerosis are more significant.

(The picture shows the effects of sharing 180 μg/vitamin K2 (MK-7) on the effect of nattoin kinase)

(The picture shows the effect of sharing 100mg/day aspirin on the effect of nattoin kinase)

This clinical study in the field of nan bean kinase has significant significance and practical influence in preventing cardiovascular health.

Through detailed clinical data, people can see the research prospects of nattokine in the field of cardiovascular fields such as inhibitory atherosclerosis and controlling hyperlipidemia, showing a new breakthrough in human prevention and maintenance of cardiovascular health.

The research results reveal the importance of healthy lifestyle on cardiovascular health risks, and also have new guiding significance for people with bad lifestyles to prevent cardiovascular health. From a higher perspective, this clinical study has a positive boost influence on human health and my country's "healthy China" strategy.

It is understood that the nan bean kinase preparation products used in this study were approved by the National Medical Products Administration of China (NMPA) and were produced by Guangdong Shuangjun Biotechnology Co., Ltd..The study promoted the understanding of the role of nattoinobinase and the importance of the selection dose. It is reported that this is also one of the clinical research projects carried out in the Shuangjun Bio "Natto Koba Lart Project".Literature source:

Participants. Front. Cardiovasc. MED. 9: 964977. Doi: 10.3389/FCVM.2022.9649777

Source: Biological Valley

- END -